AbbVie Holdings Cut by Investment Firm

Miller Howard Investments Inc. NY reduced its stake in the pharmaceutical company by 1.3% in Q4 2025.

Apr. 20, 2026 at 10:14am

Got story updates? Submit your updates here. ›

An extreme close-up of complex, industrial pharmaceutical manufacturing equipment and machinery, conveying the scale and power of the pharmaceutical industry without using any text or branding.An institutional investor's reduced stake in the pharmaceutical company AbbVie reflects broader shifts in market sentiment.North Chicago Today

Miller Howard Investments Inc. NY, an institutional investor, reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.3% in the fourth quarter of 2025, according to a filing with the Securities and Exchange Commission (SEC). The firm now owns 401,292 shares of the pharmaceutical company's stock, valued at $91,691,000.

Why it matters

AbbVie is a major pharmaceutical company with a diverse portfolio of drugs, so changes in institutional ownership can signal shifts in investor sentiment and market expectations for the company's performance.

The details

According to the SEC filing, Miller Howard Investments Inc. NY sold 5,439 shares of AbbVie stock during the fourth quarter. The firm's holdings in AbbVie now make up 2.8% of its total investment portfolio, making it the 5th largest position.

  • The filing covers the fourth quarter of 2025.
  • Miller Howard Investments Inc. NY reduced its AbbVie stake by 1.3% during this period.

The players

Miller Howard Investments Inc. NY

An institutional investor that owns a sizable stake in AbbVie Inc.

AbbVie Inc.

A global biopharmaceutical company that focuses on developing and commercializing specialty medicines across multiple therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

This reduction in institutional ownership of AbbVie shares, even if relatively small, could signal a shift in investor sentiment towards the company and its future prospects. It's a data point worth monitoring as part of the broader analysis of AbbVie's performance and outlook.